CCL3 and Miyoshi myopathy: The peptide is involved in the regulation of the production of several proinflammatory mediators (e.g., TNF-α, IL-6, MIP-1α) and may affect the complex cytokine network of the bone marrow microenvironment, which is altered by the MM cells, influencing the course and progression of the disease and the development of various end-organ damage [23,27,28].